- Home
- ESPR vs DCGO Comparison
ESPR vs DCGO Comparison
Compare ESPR & DCGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- DCGO
- Stock Information
- Founded
- ESPR 2008
- DCGO 2015
- Country
- ESPR United States
- DCGO United States
- Employees
- ESPR N/A
- DCGO N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- DCGO Managed Health Care
- Sector
- ESPR Health Care
- DCGO Health Care
- Exchange
- ESPR Nasdaq
- DCGO Nasdaq
- Market Cap
- ESPR 410.2M
- DCGO 415.2M
- IPO Year
- ESPR 2013
- DCGO N/A
- Fundamental
- Price
- ESPR $1.89
- DCGO $4.94
- Analyst Decision
- ESPR Buy
- DCGO Strong Buy
- Analyst Count
- ESPR 6
- DCGO 5
- Target Price
- ESPR $7.25
- DCGO $6.10
- AVG Volume (30 Days)
- ESPR 5.1M
- DCGO 434.9K
- Earning Date
- ESPR 02-25-2025
- DCGO 02-26-2025
- Dividend Yield
- ESPR N/A
- DCGO N/A
- EPS Growth
- ESPR N/A
- DCGO 300.38
- EPS
- ESPR N/A
- DCGO 0.29
- Revenue
- ESPR $295,451,000.00
- DCGO $694,968,328.00
- Revenue This Year
- ESPR $186.04
- DCGO $2.14
- Revenue Next Year
- ESPR $11.25
- DCGO N/A
- P/E Ratio
- ESPR N/A
- DCGO $17.35
- Revenue Growth
- ESPR 187.12
- DCGO 30.19
- 52 Week Low
- ESPR $1.58
- DCGO $2.75
- 52 Week High
- ESPR $3.94
- DCGO $5.12
- Technical
- Relative Strength Index (RSI)
- ESPR 39.38
- DCGO 65.01
- Support Level
- ESPR $1.71
- DCGO $4.70
- Resistance Level
- ESPR $2.26
- DCGO $5.12
- Average True Range (ATR)
- ESPR 0.14
- DCGO 0.22
- MACD
- ESPR -0.01
- DCGO 0.04
- Stochastic Oscillator
- ESPR 33.33
- DCGO 82.61
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About DCGO DocGo Inc.
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company has three reportable segments: Mobile Health Services, Transportation Services, and Corporate. Mobile Health Services is the key revenue-generating segment for the company.